Literature DB >> 29219960

Exploring factors predicting changes in patients' expectations and psychosocial issues during the course of treatment with intravitreal injections for wet age-related macular degeneration.

S Sii1, P Aspinall2,3, S Borooah4,5, B Dhillon5,6.   

Abstract

PurposePatients with wet age-related macular degeneration (AMD) often require long courses of treatment. We investigate the psychosocial issues that could hinder compliance, including patient expectations of treatment. The aims of this study were to explore the factors related to changes in patient expectations, pain, and anxiety during treatment.Patients and methodsA structured interview was carried out among 50 patients selected from the list attending the AMD unit at the Princess Alexandra Eye Pavilion (PAEP). The interview was based on a questionnaire. Additionally, a visual analogue scale was created as a tool for measuring patient expectations, pain, and anxiety. Data were analysed using multinomial regression analysis.ResultsThere were significantly more patients who had a fall in expectations (P<0.05) during the course of treatment. A fall in expectations was found to be predicted by higher starting expectations (P=0.00001), greater decline in visual acuity (P=0.008), and perceived deterioration of vision after starting treatment (P=0.013). Of the patients, 32% planned to stop attending for further injections. Planning to stop attending was correlated with worse final visual acuity (P=0.026, 95% CI). Pain and anxiety with intravitreal therapy (IVT) was significantly reduced when patients were accompanied to the clinic by a friend or relative (P<0.01) using Pearson's correlation (r=0.597).ConclusionPatients require appropriate counselling at the start of a course of treatment to align expectations with perceived treatment outcomes in order to improve adherence. Additionally, a large minority of patients would consider stopping treatment. Patients' expectations should be assessed at relevant time points along a course of treatment.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29219960      PMCID: PMC5898856          DOI: 10.1038/eye.2017.271

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  20 in total

Review 1.  Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges.

Authors:  Jordana K Schmier; Carolyn K Hulme-Lowe
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

Review 2.  The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis.

Authors:  Tien Y Wong; Tien Wong; Usha Chakravarthy; Ronald Klein; Paul Mitchell; Gergana Zlateva; Ronald Buggage; Kyle Fahrbach; Corey Probst; Isabella Sledge
Journal:  Ophthalmology       Date:  2007-08-06       Impact factor: 12.079

3.  Six-year outcomes in neovascular age-related macular degeneration with ranibizumab.

Authors:  Julie Jacob; Heidi Brié; Anita Leys; Laurent Levecq; Filip Mergaerts; Kris Denhaerynck; Stefaan Vancayzeele; Eline Van Craeyveld; Ivo Abraham; Karen MacDonald
Journal:  Int J Ophthalmol       Date:  2017-01-18       Impact factor: 1.779

4.  Evaluating patient discomfort, anxiety, and fear before and after ranibizumab intravitreous injection for wet age-related macular degeneration.

Authors:  Paul Yih Seng Chua; Izabela Mitrut; Ana-Marie Armbrecht; Archana Vani; Tariq Aslam; Baljean Dhillon
Journal:  Arch Ophthalmol       Date:  2009-07

5.  Licence to save: a UK survey of anti-VEGF use for the eye in 2015.

Authors:  A K Shalaby; K Lewis; K Bush; P R Meredith; S Di Simplicio; A J Lockwood
Journal:  Eye (Lond)       Date:  2016-08-12       Impact factor: 3.775

6.  Effects of music therapy on intravitreal injections: a randomized clinical trial.

Authors:  Xuejing Chen; Rajeev K Seth; Veena S Rao; John J Huang; Ron A Adelman
Journal:  J Ocul Pharmacol Ther       Date:  2012-04-16       Impact factor: 2.671

7.  Trends over time and geographical variation in rates of intravitreal injections in England.

Authors:  Tiarnan D L Keenan; Clare J Wotton; Michael J Goldacre
Journal:  Br J Ophthalmol       Date:  2011-08-28       Impact factor: 4.638

Review 8.  Is significant relevant? Validity and patient benefit of randomized controlled clinical trials on age-related macular degeneration.

Authors:  Antonia M Joussen; Walter Lehmacher; Ralf-Dieter Hilgers; Bernd Kirchhof
Journal:  Surv Ophthalmol       Date:  2007 May-Jun       Impact factor: 6.048

9.  Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials.

Authors:  P Mitchell; J-F Korobelnik; P Lanzetta; F G Holz; C Prünte; U Schmidt-Erfurth; Y Tano; S Wolf
Journal:  Br J Ophthalmol       Date:  2009-05-13       Impact factor: 4.638

10.  Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes.

Authors:  Meidong Zhu; Jamie K Chew; Geoffrey K Broadhead; Kehui Luo; Nichole Joachim; Thomas Hong; Adil Syed; Andrew A Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-09-10       Impact factor: 3.117

View more
  4 in total

1.  Evaluation of Anxiety Levels in Patients Undergoing Intravitreal Injections and Associated Risk Factors Related to the Disease.

Authors:  Juan-Carlos Herranz-Heras; Almudena de-Pablo-Cabrera; Beatriz Alonso-Martín; Beatriz de-Lucas-Viejo; Marta de-Castro-Liébana; Enrique Mencía-Gutiérrez; Manuel-Jesús Ferro-Osuna; Carmen Romero; Javier Sambricio
Journal:  J Ophthalmol       Date:  2020-10-19       Impact factor: 1.909

2.  Impact of a Patient Support Program on Patient Beliefs About Neovascular Age-Related Macular Degeneration and Persistence to Anti-Vascular Endothelial Growth Factor Therapy.

Authors:  Andrew Chang; John Stokes; Lindy Priestman; Connor Holmes; Peter Said
Journal:  Patient Prefer Adherence       Date:  2021-03-03       Impact factor: 2.711

3.  Factors Associated with Pain Level in Patients Receiving Intravitreal Injection.

Authors:  Ali İnaltekin; Erdinç Bozkurt; Yüksel Kıvrak
Journal:  J Curr Ophthalmol       Date:  2021-10-22

4.  [The Hamburg register for intravitreal injection therapies (QIVOM)].

Authors:  Christian Wolfram; Marc Schargus
Journal:  Ophthalmologe       Date:  2021-08-20       Impact factor: 1.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.